KaydedilenlerDerginizi ekleyin

Dergiler / Atlas Journal of Medicine / 2026 / Cilt: 6 Sayı: Özel Sayı 1 Özel Sayı

Meme kanserinde aksiller tedavide güncel yaklaşım

Current Approach in Axillary Treatment of Breast Cancer

Emine Yıldırım(İSTANBUL ATLAS ÜNİVERSİTESİ, TIP FAKÜLTESİ)0000-0003-2733-402X
Sayfa
12–19
Yayın Tarihi
2026-05-08
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Yaptığımız çalışmada meme kanserinin aksiller tedavisinin geçmişini ve geleceğini irdeledik.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Meme kanseri tedavisinde aksiller cerrahi çok uzun zamandır lokal kontrolü sağlamak ve hastalığı doğru evrelemek için uygulanmaktadır.
📊
Temel Bulgular & Veri:Günümüzde cerrahi tedaviye bağlı komplikasyonları azaltmak ve de-eskalasyonu sağlamak için yapılan çalışmalar meme kanserinde aksiller cerrahide de daha az invaziv yöntemler gelişmesini sağlamıştır.
💡
Sonuç & Katkı:Yaptığımız çalışmada meme kanserinin aksiller tedavisinin geçmişini ve geleceğini irdeledik.
🔬Tür:Derleme
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Meme kanseri · aksiller lenf nodu diseksiyonu · sentinel lenf nodu biyopsisi

Özet

Meme kanseri tedavisinde aksiller cerrahi çok uzun zamandır lokal kontrolü sağlamak ve hastalığı doğru evrelemek için uygulanmaktadır. Günümüzde cerrahi tedaviye bağlı komplikasyonları azaltmak ve de-eskalasyonu sağlamak için yapılan çalışmalar meme kanserinde aksiller cerrahide de daha az invaziv yöntemler gelişmesini sağlamıştır. Yaptığımız çalışmada meme kanserinin aksiller tedavisinin geçmişini ve geleceğini irdeledik.

Abstract

Axillary surgery in the treatment of breast cancer has long been used for local control and accurate staging of the disease. Today, efforts to reduce complications related to surgical treatment and to provide de-escalation have led to the development of less invasive methods in axillary surgery in breast cancer. In this study, we analyzed the past and future of axillary treatment of breast cancer.

🔖

Bu Makaleye Atıf Yap

Yıldırım, E. (2026). Meme kanserinde aksiller tedavide güncel yaklaşım. Atlas Journal of Medicine, Cilt: 6 Sayı: Özel Sayı 1 Özel Sayı, 12–19. https://doi.org/10.54270/atljm.2026.118

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (36)

  1. Ekmektzoglou KA, Xanthos T, German V, et al. Breast cancer: from the earliest times through to the end of the 20th century. Eur J Obstet Gynecol Reprod Biol. 2009 Jul;145(1):3-8. doi: 10.1016/j.ejogrb.2009.03.017.
  2. Rao R. The Evolution of Axillary Staging in Breast Cancer. Mo Med. 2015 Sep-Oct;112(5):385-8. PMID: 26606821.
  3. Swenson KK, Nissen MJ, Ceronsky C, et al. Comparison of side effects between sentinel lymph node and axillary lymph node dissection for breast cancer. Ann Surg Oncol. 2002;9(8):745–753. doi: 10.1007/BF02574496.
  4. Langer I, Marti WR, Guller U, et al. Axillary recurrence rate in breast cancer patients with negative sentinel lymph node (SLN) or SLN micrometastases: prospective analysis of 150 patients after SLN biopsy. Ann Surg. 2005 Jan;241(1):152-8. doi: 10.1097/01.sla.0000149305.23322.3c.
  5. Krag DN, Julian TB, Harlow SP, et al. NSABP-32: Phase III, randomized trial comparing axillary resection with sentinal lymph node dissection: a description of the trial. Ann Surg Oncol. 2004 Mar;11(3 Suppl):208S-10S. doi: 10.1007/BF02523630.
  6. Lyman GH, Somerfield MR, Bosserman LD, et al. Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2017 Feb 10;35(5):561-564. doi: 10.1200/JCO.2016.71.0947.
  7. Intra M, Viale G, Vila J, et al. Second axillary sentinel lymph node biopsy for breast tumor recurrence: experience of the European Institute of Oncology. Ann Surg Oncol. 2015;22(7):2372–2377. doi: 10.1245/s10434-014-4282-5.
  8. Port ER, Garcia-Etienne CA, Park J, et al. Reoperative sentinel lymph node biopsy: a new frontier in the management of ipsilateral breast tumor recurrence. Ann Surg Oncol. 2007;14(8):2209–2214. doi: 10.1245/s10434-006-9237-z.
  9. Boughey JC, Suman VJ, Mittendorf EA, et al Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013 Oct 9;310(14):1455-61. doi: 10.1001/jama.2013.278932.
  10. Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013 Jun;14(7):609-18. doi: 10.1016/S1470-2045(13)70166-9.
  11. Mamounas EP, Brown A, Anderson S, et al. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2005 Apr 20;23(12):2694-702. doi: 10.1200/JCO.2005.05.188.
  12. Classe JM, Loaec C, Gimbergues P, et al. Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study. Breast Cancer Res Treat. 2019 Jan;173(2):343-352. doi: 10.1007/s10549-018-5004-7.
  13. Sagara Y, Kuba S, Maeda S et al. 321P Sentinel lymph node biopsy in clinical T3-4c breast cancer: A retrospective multicenter cohort study. Annals of Oncology. 2024 Sept; 35: 349
  14. de Oliveira-Junior I, Nahas EAP, Cherem AC, et al. Sentinel Lymph Node Biopsy in T3 and T4b Breast Cancer Patients: Analysis in a Tertiary Cancer Hospital and Systematic Literature Review. Breast Care (Basel). 2021 Feb;16(1):27-35. doi: 10.1159/000504693.
  15. Cao S, Liu X, Cui J, et al. Feasibility and reliability of sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer patients with positive axillary nodes at initial diagnosis: An up-to-date meta-analysis of 3,578 patients. Breast. 2021 Oct;59:256-269. doi: 10.1016/j.breast.2021.07.01.
  16. DeSnyder SM, Mittendorf EA, Le-Petross C, et al. Prospective Feasibility Trial of Sentinel Lymph Node Biopsy in the Setting of Inflammatory Breast Cancer. Clin Breast Cancer. 2018 Feb;18(1):e73-e77. doi: 10.1016/j.clbc.2017.06.014.
  17. Bothou Α, Margioula-Siarkou C, Petousis S, et al. Sentinel lymph node biopsy for breast cancer during pregnancy: A comprehensive update. Eur J Clin Invest. 2024 Mar;54(3):e14134. doi: 10.1111/eci.14134.
  18. Giammarile F, Vidal-Sicart S, Paez D, et al. Sentinel Lymph Node Methods in Breast Cancer. Semin Nucl Med. 2022 Sep;52(5):551-560. doi: 10.1053/j.semnuclmed.2022.01.006.
  19. van der Ploeg IM, Nieweg OE, van Rijk MC, et al. Axillary recurrence after a tumour-negative sentinel node biopsy in breast cancer patients: A systematic review and meta-analysis of the literature. Eur J Surg Oncol. 2008 Dec;34(12):1277-84. doi: 10.1016/j.ejso.2008.01.034.
  20. Wong SL, Edwards MJ, Chao C et al. Predicting the status of the nonsentinel axillary nodes: a multicenter study. Arch Surg 2001; 136: 563‐8.
  21. Bartels SAL, Donker M, Poncet Cet al. Radiotherapy or Surgery of the Axilla After a Positive Sentinel Node in Breast Cancer: 10-Year Results of the Randomized Controlled EORTC 10981-22023 AMAROS Trial. J Clin Oncol. 2023 Apr 20;41(12):2159-2165. doi: 10.1200/JCO.22.01565
  22. Sávolt Á, Péley G, Polgár C, et al. Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial. Eur J Surg Oncol. 2017 Apr;43(4):672-679. doi: 10.1016/j.ejso.2016.12.011.
  23. Galimberti V, Cole BF, Viale G, et al. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial. Lancet Oncol. 2018 Oct;19(10):1385-1393. doi: 10.1016/S1470-2045(18)30380-2.
  24. Giuliano AE, Ballman KV, McCall L, et al. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial. JAMA. 2017 Sep 12;318(10):918-926. doi: 10.1001/jama.2017.11470.
  25. Caudle AS, Yang WT, Krishnamurthy S, et al. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol. 2016;34(10):1072–1078. doi: 10.1200/JCO.2015.64.0094.
  26. van Hemert AKE, van Duijnhoven FH, Vrancken Peeters MTFD. This house believes that: MARI/TAD is better than sentinel node biopsy after PST for cN+ patients. Breast. 2023 Oct;71:89-95. doi: 10.1016/j.breast.2023.06.011.
  27. Gentilini OD, Botteri E, Sangalli C, et al. SOUND Trial Group. Sentinel Lymph Node Biopsy vs No Axillary Surgery in Patients With Small Breast Cancer and Negative Results on Ultrasonography of Axillary Lymph Nodes: The SOUND Randomized Clinical Trial. JAMA Oncol. 2023 Nov 1;9(11):1557-1564. doi: 10.1001/jamaoncol.2023.3759.
  28. Kartal E, Kayhan A, Gündüz N, Dağıstanlı S. Molecular subtypes of breast cancer: Can it be determinant for preoperative MRI planning? Ege Klin Tip Derg. 2024;62(1):59-72.
  29. Yildirim E, Basim P, Ucar N, et al. Management of the Axilla After Neoadjuvant Chemotherapy: Can Axillary Needle Biopsy Replace Sentinel Node Biopsy? In Vivo. 2024 Sep-Oct;38(5):2523-2530. doi: 10.21873/invivo.13724.
  30. Reimer T, Stachs A, Veselinovic K, et al. Axillary Surgery in Breast Cancer - Primary Results of the INSEMA Trial. N Engl J Med. 2025 Mar 13;392(11):1051-1064. doi: 10.1056/NEJMoa2412063.
  31. Banys-Paluchowski M, Gasparri ML, de Boniface J, et al. Surgical Management of the Axilla in Clinically Node-Positive Breast Cancer Patients Converting to Clinical Node Negativity through Neoadjuvant Chemotherapy: Current Status, Knowledge Gaps, and Rationale for the EUBREAST-03 AXSANA Study. Cancers (Basel). 2021 Mar 29;13(7):1565. doi: 10.3390/cancers13071565]
  32. Judy Boughey MD, Bruce Haffty MD, Thomas Buchholz MD, et.al. Alliance A011202: A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Receiving Neoadjuvant Chemotherapy. [Last acces 28.02.2025], from https://www.bestofsabcs.com/videohighlights?i=T_qJS1pMeP-iqnq8JJ81c9y6lLBYd_NI
  33. Goyal A, Mann GB, Fallowfield L, et al. POSNOC-POsitive Sentinel NOde: adjuvant therapy alone versus adjuvant therapy plus Clearance or axillary radiotherapy: a randomised controlled trial of axillary treatment in women with early-stage breast cancer who have metastases in one or two sentinel nodes. BMJ Open. 2021 Dec 2;11(12):e054365. doi: 10.1136/bmjopen-2021-054365
  34. Amit Goyal, Sophie Cramp, Andrea Marshall et al. ATNEC: A multicenter, randomized trial investigating whether axillary treatment can be avoided in patients with T1-3N1M0 breast cancer with no residual cancer in the lymph glands after neoadjuvant chemotherapy. Journal of Clinical Oncology 2022 40:16_suppl, TPS615-TPS615 doi:10.1200/JCO.2022.40.16_suppl.TPS615
  35. Tinterri C, Canavese G, Bruzzi P, et al. NEONOD 2: Rationale and design of a multicenter non-inferiority trial to assess the effect of axillary surgery omission on the outcome of breast cancer patients presenting only micrometastasis in the sentinel lymph node after neoadjuvant chemotherapy. Contemp Clin Trials Commun. 2019 Nov 23;17:100496. doi: 10.1016/j.conctc.2019.100496.
  36. Potter S, Avery K, Dodwell D, et al. Targeted Axillary Dissection versus axillary node clearance in patients with POsitive axillary Lymph nodes in Early breast cancer: A multicentre, pragmatic, phase III randomised controlled trial. [Last acces 28.02.2025], from https://tadpole.blogs.bristol.ac.uk/